Evidence map›Paper›PMID 34429847›Full record

ArticleComputational and structural biotechnology journal2021

Engineering a new vaccine platform for heterologous antigen delivery in live-attenuated

Esther Broset, Juan Calvet Seral, Carmen Arnal, Santiago Uranga, Alex I Kanno, Luciana C C Leite, Carlos Martín, Jesús Gonzalo-Asensio

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Computational and structural biotechnology journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. RecombinantVaccines · 2025
    Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Esther BrosetGrupo de Genética de Micobacterias, Departamento de Microbiología, Facultad de Medicina, Universidad de Zaragoza, IIS-Aragón, 50009 Zaragoza, Spain.
Juan Calvet SeralGrupo de Genética de Micobacterias, Departamento de Microbiología, Facultad de Medicina, Universidad de Zaragoza, IIS-Aragón, 50009 Zaragoza, Spain.
Carmen ArnalGrupo de Genética de Micobacterias, Departamento de Microbiología, Facultad de Medicina, Universidad de Zaragoza, IIS-Aragón, 50009 Zaragoza, Spain.
Santiago UrangaGrupo de Genética de Micobacterias, Departamento de Microbiología, Facultad de Medicina, Universidad de Zaragoza, IIS-Aragón, 50009 Zaragoza, Spain.
Alex I KannoLaboratório de Desenvolvimento de Vacinas, Instituto Butantan, Av. Vital Brasil 1500, 05503-900 São Paulo, Brazil.
Luciana C C LeiteLaboratório de Desenvolvimento de Vacinas, Instituto Butantan, Av. Vital Brasil 1500, 05503-900 São Paulo, Brazil.
Carlos MartínGrupo de Genética de Micobacterias, Departamento de Microbiología, Facultad de Medicina, Universidad de Zaragoza, IIS-Aragón, 50009 Zaragoza, Spain.
Jesús Gonzalo-AsensioGrupo de Genética de Micobacterias, Departamento de Microbiología, Facultad de Medicina, Universidad de Zaragoza, IIS-Aragón, 50009 Zaragoza, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Live vaccines are attractive vehicles for antigen delivery as a strategy to immunize against heterologous pathogens. The live vaccine MTBVAC is based on rational attenuation of

Indexed as

BCGDTP antigensFastidious bacteriaMTBVACSynthetic biologyTuberculosis vaccineTwin arginine translocation (TAT)

Identifiers

PMID34429847
PMCPMC8355830

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.